UK Preeclampsia Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Test, Use, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
UK · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$34.0 MnPlaceholder estimate
Estimate 2025$35.6 Mn2.2% of the global market
Projected 2034$54.3 Mn 52.5%Adds $18.7 Mn over 9 forecast years
CAGR 2025–20344.8%Faster than 27% of 173 Medical Devices markets here
6 in the UKSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The UK Preeclampsia Diagnostics Market Analysis Executive Summary
Preeclampsia diagnostics are blood tests and monitoring tools that predict or detect dangerous high blood pressure in pregnancy.
Key segments of the preeclampsia Diagnostics market include test (sFlt-1/PlGF Ratio Tests, PlGF Tests and Blood Pressure Monitoring) and use (Screening, Diagnosis and Prognosis).
UK Preeclampsia Diagnostics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
UK Preeclampsia Diagnostics Market Dynamics
Market Growth Drivers
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the preeclampsia Diagnostics market. New products designed around women's biology and digital care are improving access.
Opportunity
Femtech, personalised care and new treatments for under-served conditions open strong growth for the preeclampsia Diagnostics market, especially as employers and payers add women's health benefits.
Market Restraints
Under-diagnosis, stigma around some conditions, limited insurance coverage and a long history of under-research in women's health hold back the preeclampsia Diagnostics market.
Competitive Landscape for Preeclampsia Diagnostics Market in UK
The preeclampsia Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Preeclampsia Diagnostics Market in UK
Preeclampsia Diagnostics in the UK: rules, payment and research
Medical devices sold in Great Britain need UKCA or CE marking and registration with the Medicines and Healthcare products Regulatory Agency (MHRA).[1] The NHS gives care that is free at the point of use; in England, NICE advises which medicines and treatments the NHS should fund.[2] ClinicalTrials.gov lists 6 studies on Preeclampsia Diagnostics that are recruiting, active or about to start in the UK.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how preeclampsia Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in UK.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Test
4.2 By Use
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Roche Diagnostics
7.2 Thermo Fisher Scientific
7.3 PerkinElmer (Revvity)
7.4 Siemens Healthineers
7.5 QuidelOrtho
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The preeclampsia Diagnostics market can be segmented based on various criteria, including test, use and end user. Here's a breakdown of the market segmentation
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Preeclampsia Diagnostics in context
The UK compared
Health spending per person: 5,860 US$ per person (2024). World: 1,317 US$ per person (2023). 2nd highest of the 6 countries we cover in Europe.[1]
Doctors: 3.30 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 5th highest of the 6 countries we cover in Europe.[2]
People aged 65 and over: 19.7% of people (2025). World: 10.4% of people (2025). 5th highest of the 6 countries we cover in Europe.[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
How big is the Preeclampsia Diagnostics market in the UK?
Placeholder estimate: about $35.6 Mn in 2025, rising to about $54.3 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Preeclampsia Diagnostics market in the UK growing?
Placeholder estimate: about 4.8% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Preeclampsia Diagnostics market report cover?
The report splits the market by test (sFlt-1/PlGF Ratio Tests, PlGF Tests, Blood Pressure Monitoring, Urine Protein Tests), use (Screening, Diagnosis, Prognosis) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Preeclampsia Diagnostics market?
Key players include Roche Diagnostics, Thermo Fisher Scientific Inc., Perkin Elmer, Siemens Healthineers and Quidel Corporation.
What is driving the Preeclampsia Diagnostics market?
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the preeclampsia Diagnostics market. New products designed around women's biology and digital care are improving access.
Who regulates Preeclampsia Diagnostics in the UK?
Medical devices sold in Great Britain need UKCA or CE marking and registration with the Medicines and Healthcare products Regulatory Agency (MHRA). Source: Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
How is healthcare paid for in the UK?
The NHS gives care that is free at the point of use; in England, NICE advises which medicines and treatments the NHS should fund. Source: National Institute for Health and Care Excellence. Checked 14 Nov 2026.
How many clinical trials on Preeclampsia Diagnostics are running in the UK?
6 studies are recruiting, active or about to start in the UK, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.
How much research is published on Preeclampsia Diagnostics?
PubMed lists 7,556 papers on Preeclampsia Diagnostics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.